All lobbying filings

FORBES-TATE

Lobbying for CSL BEHRING · Biopharmaceutical Company

Filing 3rd Quarter - Termination

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 10, 2025

Income

$60,000.00

What the client paid this registrant for the period.

Client based in

Pennsylvania

Representation ended

Sep 30, 2025

The registrant reported terminating its work for this client.

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 2

Medical/Disease Research/Clinical Labs

Issues related to biopharmaceutical pricing; Issues related to plasma and plasma derived therapies; Issues related to the Preserving Life-saving Access to Specialty Medicines in America Act.

Medicare/Medicaid

Issues related to biopharmaceutical pricing; Issues related to plasma and plasma derived therapies.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.